Navigation Links
Valeant Pharmaceuticals And Obagi Medical Products Agree On An Increased Offer Price Of $24.00 Per Share In Cash
Date:4/3/2013

, future developments or otherwise.

Additional Information and Where to Find It

This announcement is neither an offer to purchase nor a solicitation of an offer to sell shares of Obagi. Valeant has filed a Tender Offer Statement on Schedule TO with the U.S. Securities and Exchange Commission on March 26, 2013, and Obagi has filed a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the offer on March 26, 2013. Valeant expects to file an amendment to the Schedule TO, and Obagi is expected to file an amendment to the Schedule 14D-9 to reflect the new offer price.  Stockholders and other investors are urged to read the tender offer materials (including an Offer to Purchase, a related Letter of Transmittal and certain other offer documents) and the Solicitation/Recommendation Statement, in each case as amended (to the extent applicable), because they contain important information which should be read carefully before any decision is made with respect to the tender offer. The Offer to Purchase, the related Letter of Transmittal and certain other offer documents, as well as the Solicitation/Recommendation Statement, have been made available to all stockholders of Obagi at no expense to them. The Tender Offer Statement and the Solicitation/Recommendation Statement are available for free at the Commission's web site at www.sec.gov. In addition, the tender offer statement and other documents that Valeant files with the SEC are and will be made available to all stockholders of Obagi free of charge at www.valeant.com. The solicitation/recommendation statement and the other documents filed by Obagi with the SEC are and will be made available to all stockholders of Obagi free of charge at www.obagi.com.

Contact Information:

Laurie W. Little
949-461-6002

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Valeant Pharmaceuticals Announces Private Exchange Offer
2. Valeant Pharmaceuticals International, Inc. Agrees to Acquire Obagi Medical Products, Inc. for $19.75 Per Share in Cash
3. Valeant Pharmaceuticals Reports 2012 Fourth Quarter Financial Results
4. Valeant Completes Acquisition Of Natur Produkt In Russia
5. Valeant Pharmaceuticals To Announce 2012 Fourth Quarter Results On February 28, 2013
6. Valeant Completes Acquisition of Medicis and Announces Date of 2013 Financial Guidance Conference Call
7. Valeant Pharmaceuticals And Galderma Agree On Revised Agreement Terms
8. Valeant Pharmaceuticals Announces New Management Appointments
9. Valeant Pharmaceuticals Announces Publication of Efinaconazole Phase III Results
10. Valeant Pharmaceuticals Annonces New $1.5 Billion Securites Repurchase Program
11. Valeant Pharmaceuticals Receives FTC Clearance For Medicis Acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Calif. , Jan. 15, 2014 Massachusetts ... (NASDAQ: AMGN ) announced today that ... discover and validate new therapeutic targets and develop ... chronic disorder that affects millions worldwide. The MGH-Broad-Amgen ...
(Date:1/15/2014)... BEACH GARDENS, Fla. , Jan. 15, 2014  In an unprecedented ... difficile and TB in ambulances and other transport vehicles, an advanced ... used by rescue personnel for the first time. ... in contact with these deadly pathogens, West Palm Beach ...
(Date:1/15/2014)... 2014  According to Millennium Research Group (MRG), the ... the United States and European ... expand moderately through 2022, with embolization particles representing ... interest in drug-eluting beads (DEBs) and radioembolization spheres ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Superbugs No Longer Ride In Rescue Vehicles 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... Fla., March 22, 2011 GeNO LLC ( ... company, today announced commencement of  the PHiano Study: ... of Pulmonary Hypertension in patients with Pulmonary Arterial ... Pulmonary Fibrosis (PH-IPF) using Inhaled NITROSYL™ nitric oxide ...
... Dry, dull skin can get you down in the ... professor and chair of the department of dermatology at Wake ... AmLactin® twice a day, seven days a week to get ... clinically proven alpha-hydroxy acid, 12% lactic acid, to gently exfoliate ...
Cached Medicine Technology:GeNO LLC Initiates Study of Inhaled NITROSYLâ„¢ Nitric Oxide in Idiopathic Pulmonary Fibrosis (PH-IPF) and Pulmonary Arterial Hypertension (PAH) Patients 2GeNO LLC Initiates Study of Inhaled NITROSYLâ„¢ Nitric Oxide in Idiopathic Pulmonary Fibrosis (PH-IPF) and Pulmonary Arterial Hypertension (PAH) Patients 3Does Your Skin Need Therapy? 2Does Your Skin Need Therapy? 3
(Date:4/17/2014)... April 17, 2014 EcoHealth Alliance, a nonprofit organization ... published a comprehensive review today examining the current state ... The review calls for improved global surveillance strategies to ... recent outbreak of Ebola in West Africa that has ... of Guinea and Liberia. According to the World ...
(Date:4/17/2014)... to find a colored ribbon representing a disease. A pink ... color ribbon does one think of with lung cancer?, Although ... suffering from the disease, black may be the only one ... lung cancer patients, primarily smokers between the ages of 51 ... stigma often felt by these patients, the emotional toll it ...
(Date:4/17/2014)... of Canadians surveyed said they would participate in public ... of genetic conditions, only 80 per cent said they ... sequence their newborns, genomes.,Most newborns in North America have ... two of life in which a tiny amount of ... about five to 54 conditions, depending on the state ...
(Date:4/16/2014)... , STANFORD, Calif. Consider the marvel of the embryo. ... shape and function as they multiply to become the cells ... tissues of the body. , Now, in a feat of ... the complex genetic coding that allows embryonic cells to proliferate ...
(Date:4/16/2014)... fertility treatments are the leading cause of increases in ... of premature birth, these results are not inevitable, concludes ... . The article identifies six changes in policy and ... and prematurity, including expanding insurance coverage for in vitro ...
Breaking Medicine News(10 mins):Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Unraveling the 'black ribbon' around lung cancer 2Health News:Researcher looks at public perceptions around newborn testing 2Health News:Researcher looks at public perceptions around newborn testing 3Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 3Health News:Preterm births, multiples, and fertility treatment 2Health News:Preterm births, multiples, and fertility treatment 3
... Transcept,Pharmaceuticals, Inc. today announced that Glenn A. Oclassen, ... 2008 Merrill Lynch Global,Pharmaceutical, Biotechnology and Medical Device ... City on Tuesday, February 5, 2008 at 8:40 ... Pharmaceuticals, Inc. is a specialty pharmaceutical company,deriving significant ...
... Feel Their Overall Health Affects Their,Recovery from Schizophrenia, ... Health,America of San Diego today released results of ... in mental health settings from the,perspective of both ... both groups are aware of actions to improve ...
... Baby Products, With Information, on the Best Baby Products and Easy-To-Follow ... ... Well, NORCROSS, Georgia, January 29 BabySupply.Info, has,launched today ... opportunity to save time and,money with a shopping comparison engine for baby ...
... Cause To Support Stefanie LaRue and Her Fight to,Live, ... cancer survivor Stefanie LaRue, known nationally as the "Breast,Cancer ... breast,cancer, is being honored at a benefit concert on ... at 2701 N. Sepulveda Blvd., Los,Angeles, CA. The event, ...
... billion -- Diluted earnings per share from continuing operations increase 16,percent ... ... -- Full year Non-GAAP EPS now expected to be $3.75 ... contract, DUBLIN, Ohio, Jan. 29 Cardinal Health, a,global provider of ...
... CHICAGO, Jan. 29 Medifacts Systems, Inc. announces ... genetic test patent to Mayo,Clinic. The patented test ... of blood-related disorders. The patent is the invention ... Vicksburg, Mississippi who,was educated at Xavier University in ...
Cached Medicine News:Health News:Transcept Pharmaceuticals to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference 2Health News:First-of-Its-Kind National Online Survey Uncovers Obstacles to Comprehensive Healthcare for People With Schizophrenia 2Health News:First-of-Its-Kind National Online Survey Uncovers Obstacles to Comprehensive Healthcare for People With Schizophrenia 3Health News:First-of-Its-Kind National Online Survey Uncovers Obstacles to Comprehensive Healthcare for People With Schizophrenia 4Health News:BabySupply.Info Announces Launch of Website for New Parents 2Health News:32-Year-Old Breast Cancer Survivor, Fashion Model Featured in Benefit Concert 'Music of the Light' at Skirball Cultural Center 2Health News:32-Year-Old Breast Cancer Survivor, Fashion Model Featured in Benefit Concert 'Music of the Light' at Skirball Cultural Center 3Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 2Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 3Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 4Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 5Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 6Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 7Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 8Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 9Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 10Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 11Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 12Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 13Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 14Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 15Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 16Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 17Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 18Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 19Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 20Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 21Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 22Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 23Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 24Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 25Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 26Health News:Medifacts Systems, Inc. Grants Exclusive License for Genetic Test Patent to Mayo Clinic 2Health News:Medifacts Systems, Inc. Grants Exclusive License for Genetic Test Patent to Mayo Clinic 3